Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0047)
Name
Aspirin
Synonyms
aspirin; ACETYLSALICYLIC ACID; 50-78-2; 2-Acetoxybenzoic acid; 2-(Acetyloxy)benzoic acid; O-Acetylsalicylic acid; Acetylsalicylate; o-Acetoxybenzoic acid; Acylpyrin; Easprin; Ecotrin; Salicylic acid acetate; Acenterine; Acetophen; Acetosal; Colfarit; Polopiryna; Acetosalin; Aspirdrops; Enterosarein; Pharmacin; Premaspin; Salcetogen; Aceticyl; Acetonyl; Acetylin; Acidum acetylsalicylicum; Benaspir; Empirin; Endydol; Measurin; Rhodine; Saletin; Temperal; Ecolen; Rheumintabletten; Solprin acid; o-Carboxyphenyl acetate; Enterosarine; Acetisal; Acetylsal; Aspirine; Bialpirina; Bialpirinia; Claradin; Clariprin; Entericin; Enterophen; Globentyl; Micristin; Neuronika; Salacetin; Solpyron; Acesal; Acisal; Asagran; Asteric; Cemirit; Decaten; Duramax; Extren; Globoid; Helicon; Idragin; Levius; Pirseal; Rhonal; Solfrin; Adiro; Aspec; Aspro; Novid; Yasta; Acetosalic acid; Benzoic acid, 2-(acetyloxy)-; 2-acetyloxybenzoic acid; Spira-Dine; Bi-prin; Acimetten; Delgesic; Entrophen; Acetilum acidulatum; Acetilsalicilico; 2-Carboxyphenyl acetate; Dolean pH 8; Triple-sal; ZORprin; Contrheuma retard; XAXA; Acido acetilsalicilico; Acide acetylsalicylique; Endosprin; Persistin; A.S.A. empirin; ASA; 8-hour Bayer; Acetysal; Kapsazal; Asatard; Durlaza; Solprin; Bayer; Ronal; Acetylsalicylsaure; Rheumin tabletten; 2-Acetoxybenzenecarboxylic acid; Acetylsalycilic acid; Triaminicin; Asaphen; Crystar; Tasprin; acetyl salicylate; Aspir-Mox; Nu-seals aspirin; Salicylic acid, acetate; Acido O-acetil-benzoico; aspirin (acetylsalicylic acid); Kyselina acetylsalicylova; Durlaza ER; Acetylsalicylsaeure; Azetylsalizylsaeure; SP 189; St. Joseph Aspirin for Adults; A.S.A.; St. Joseph; Kyselina 2-acetoxybenzoova; AC 5230; Acetylsalicyclic acid; S-211; Acetylsalicylicum acidum; Aspropharm; Cardioaspirin; Acetard; CCRIS 3243; HSDB 652; CHEBI:15365; o-(Acetyloxy)benzoic acid; Acetylsalicylsaure [German]; ECM; EINECS 200-064-1; UNII-R16CO5Y76E; Bay E4465; NSC 27223; NSC-27223; acide 2-(acetyloxy)benzoique; Bayer Extra Strength Aspirin for Migraine Pain; NSC-406186; BRN 0779271; R16CO5Y76E; DTXSID5020108; Acide acetylsalicylique [French]; 2-(acetyloxy)benzoate; AI3-02956; benzoic acid, 2-acetoxy-; BAY1019036; DTXCID50108; Acetylsalicylic acid (who-ip); AXOTAL COMPONENT ASPIRIN; AZDONE COMPONENT ASPIRIN; CODOXY COMPONENT ASPIRIN; AGGRENOX COMPONENT ASPIRIN; Aspirin form II; DUOCOVER COMPONENT ASPIRIN; EXCEDRIN COMPONENT ASPIRIN; FIORINAL COMPONENT ASPIRIN; NORGESIC COMPONENT ASPIRIN; PERCODAN COMPONENT ASPIRIN; Q-GESIC COMPONENT ASPIRIN; ROXIPRIN COMPONENT ASPIRIN; VICOPRIN COMPONENT ASPIRIN; YOSPRALA COMPONENT ASPIRIN; DUOPLAVIN COMPONENT ASPIRIN; EC 200-064-1; EQUAGESIC COMPONENT ASPIRIN; INVAGESIC COMPONENT ASPIRIN; LANORINAL COMPONENT ASPIRIN; MICRAININ COMPONENT ASPIRIN; ROBAXISAL COMPONENT ASPIRIN; component of Midol; ASPIRIN COMPONENT OF AXOTAL; ASPIRIN COMPONENT OF AZDONE; ASPIRIN COMPONENT OF CODOXY; 4-10-00-00138 (Beilstein Handbook Reference); NSC27223; ORPHENGESIC COMPONENT ASPIRIN; ASPIRIN COMPONENT OF AGGRENOX; ASPIRIN COMPONENT OF DUOCOVER; ASPIRIN COMPONENT OF EXCEDRIN; ASPIRIN COMPONENT OF FIORINAL; ASPIRIN COMPONENT OF NORGESIC; ASPIRIN COMPONENT OF PERCODAN; ASPIRIN COMPONENT OF Q-GESIC; ASPIRIN COMPONENT OF ROXIPRIN; ASPIRIN COMPONENT OF VICOPRIN; ASPIRIN COMPONENT OF YOSPRALA; SYNALGOS-DC COMPONENT ASPIRIN; component of Synirin; ASPIRIN COMPONENT OF DUOPLAVIN; ASPIRIN COMPONENT OF EQUAGESIC; ASPIRIN COMPONENT OF INVAGESIC; ASPIRIN COMPONENT OF LANORINAL; ASPIRIN COMPONENT OF MICRAININ; ASPIRIN COMPONENT OF ROBAXISAL; NSC406186; component of Zactirin; MEPRO-ASPIRIN COMPONENT ASPIRIN; PERCODAN-DEMI COMPONENT ASPIRIN; PRAVIGARD PAC COMPONENT ASPIRIN; SOMA COMPOUND COMPONENT ASPIRIN; ASPIRIN COMPONENT OF ORPHENGESIC; component of Coricidin; component of Persistin; component of Robaxisal; o-Acetoxybenzoate; ASPIRIN COMPONENT OF SYNALGOS-DC; DARVON COMPOUND COMPONENT ASPIRIN; INVAGESIC FORTE COMPONENT ASPIRIN; TALWIN COMPOUND COMPONENT ASPIRIN; NCGC00015067-04; ACIDUM ACETYLSALICYLICUM (WHO-IP); ASPIRIN COMPONENT OF MEPRO-ASPIRIN; ASPIRIN COMPONENT OF PERCODAN-DEMI; ASPIRIN COMPONENT OF PRAVIGARD PAC; ASPIRIN COMPONENT OF SOMA COMPOUND; Istopirin; Magnecyl; Medisyl; Polopirin; ORPHENGESIC FORTE COMPONENT ASPIRIN; ASPIRIN COMPONENT OF DARVON COMPOUND; ASPIRIN COMPONENT OF INVAGESIC FORTE; ASPIRIN COMPONENT OF TALWIN COMPOUND; ASPIRIN (MART.); ASPIRIN [MART.]; Bayer Buffered; ASPIRIN COMPONENT OF ORPHENGESIC FORTE; Aspro Clear; component of Ascodeen-30; Bayer Plus; WLN: QVR BOV1; CARISOPRODOL COMPOUND COMPONENT ASPIRIN; AcetylsalicylicAcid; Acetylsalicylsaure (GERMAN); ASPIRIN COMPONENT OF CARISOPRODOL COMPOUND; Aspirina 03; acetyl salicylic acid; CLOPIDOGREL/ACETYLSALICYLIC ACID COMPONENT ASPIRIN; component of Darvon with A.S.A; Bayer Aspirin 8 Hour; Acide acetylsalicylique (FRENCH); Aspalon; ASPIRIN COMPONENT OF CLOPIDOGREL/ACETYLSALICYLIC ACID; Asprin; Bayer Children's Aspirin; Nu-seals; component of St. Joseph Cold Tablets; CAS-50-78-2; Acetoxybenzoic acid; Acetysalicylic acid; AIN; SMR000059138; Ascoden-30; Acid, Acetylsalicylic; Acido acetilsalicilico [Italian]; Kyselina acetylsalicylova [Czech]; Acido O-acetil-benzoico [Italian]; SR-01000075668; Kyselina 2-acetoxybenzoova [Czech]; Aspirin [USP:BAN:JAN]; Bayer Enteric 325 mg Regular Strength; Bayer Enteric 81 mg Adult Low Strength; Cardioaspirina; Acetyonyl; Angettes; Asacard; Ascolong; Aspirina; Bayer Enteric 500 mg Arthritis Strength; Cardiprin; Claragine; Colsprin; Encaprin; Miniasal; Salospir; Acesan; Toldex; Azetylsalizylsaure; ASA Empirin; 1oxr; 2-Acetoxybenzoate; Aspirin,(S); Aspalon (JAN); Durlaza (TN); Easprin (TN); MFCD00002430; acetyl-salicylic acid; VAZALORE; acetyl salicyclic acid; o-(Acetyloxy)benzoate; Percodan (Salt/Mix); Ascriptin (Salt/Mix); Micrainin (Salt/Mix); 2-acetoxy benzoic acid; RHODINE NC RP; Spectrum_001245; 2-Acetylsalicyclic acid; Acide acetyl salicylique; ASPIRIN [VANDF]; ASPIRIN [HSDB]; Salicylic acid, acetyl-; ASPIRIN [JAN]; ASPIRIN [MI]; CHEMBL25; Spectrum2_001899; Spectrum3_001295; Spectrum4_000099; Spectrum5_000740; Aspirin (JP17/USP); Lopac-A-5376; Salycylacetylsalicylic acid; ASPIRIN [USP-RS]; Epitope ID:114151; Percodan Demi (Salt/Mix); Soma Compound (Salt/Mix); Acetylsalicylic acid, 99%; cid_2244; Pravigard PAC (Salt/Mix); SCHEMBL1353; 2-(Acetyloxy)-benzoic acid; Bay-e-4465; Lopac0_000038; KBioGR_000398; KBioGR_002271; KBioSS_001725; KBioSS_002272; MLS001055329; MLS001066332; MLS001336045; MLS001336046; ASPIRIN [ORANGE BOOK]; BIDD:GT0118; DivK1c_000555; SPECTRUM1500130; SPBio_001838; Acetylsalicylic acid, >=99%; GTPL4139; ASPIRIN [USP MONOGRAPH]; O-Acetylsalicylic acid; Aspirin; BDBM22360; HMS501L17; KBio1_000555; KBio2_001725; KBio2_002271; KBio2_004293; KBio2_004839; KBio2_006861; KBio2_007407; KBio3_002149; KBio3_002751; Empirin with Codeine (Salt/Mix); Acetylsalicylic acid, >=99.0%; cMAP_000006; component of Zactirin (Salt/Mix); NINDS_000555; HMS1920E13; HMS2090G03; HMS2091K13; HMS2233L18; HMS3260G17; HMS3372N15; HMS3656N14; HMS3715P19; HMS3866L03; HMS3885G03; Pharmakon1600-01500130; ACETYLSALICYLIC ACID [INCI]; BCP21790; STR01551; ACETYLSALICYLIC ACID; ASPIRIN; Tox21_110076; Tox21_202117; Tox21_300146; Tox21_500038; CCG-39490; NSC755899; s3017; STL137674; ACETYLSALICYLIC ACID [WHO-DD]; AKOS000118884; component of Ascodeen-30 (Salt/Mix); Tox21_110076_1; ACETYLSALICYLIC ACID [EMA EPAR]; ACETYLSALICYLICUM ACIDUM [HPUS]; CS-2001; DB00945; LP00038; NSC-755899; PL-2200; SDCCGSBI-0050027.P005; BAY-1019036; IDI1_000555; ACETYLSALICYLIC ACID [GREEN BOOK]; Acetylsalicylic acid, analytical standard; NCGC00015067-01; NCGC00015067-02; NCGC00015067-03; NCGC00015067-05; NCGC00015067-06; NCGC00015067-07; NCGC00015067-08; NCGC00015067-09; NCGC00015067-10; NCGC00015067-11; NCGC00015067-12; NCGC00015067-13; NCGC00015067-14; NCGC00015067-24; NCGC00015067-26; NCGC00090977-01; NCGC00090977-02; NCGC00090977-03; NCGC00090977-04; NCGC00090977-05; NCGC00090977-06; NCGC00090977-07; NCGC00254034-01; NCGC00259666-01; NCGC00260723-01; Aspirin, meets USP testing specifications; HY-14654; NCI60_002222; ACETYLSALICYLIC ACID [EP MONOGRAPH]; SBI-0050027.P004; UNM-0000306102; component of Darvon with A.S.A (Salt/Mix); EU-0100038; FT-0655181; FT-0661360; SW199665-2; EN300-19606; A 5376; Acetylsalicylic Acid 1.0 mg/ml in Acetonitrile; C01405; D00109; E80792; Q18216; AB00051918-08; AB00051918_09; AB00051918_10; Arthritis Pain Formula Maximum Strength (Salt/Mix); SR-01000075668-1; SR-01000075668-4; SR-01000075668-6; Acetylsalicylic acid, Vetec(TM) reagent grade, >=99%; Aspirin, British Pharmacopoeia (BP) Reference Standard; F2191-0068; Z104474430; Aspirin, United States Pharmacopeia (USP) Reference Standard; D41527A7-A9EB-472D-A7FC-312821130549; Acetylsalicylic acid, European Pharmacopoeia (EP) Reference Standard; Acetylsalicylic acid, BioReagent, plant cell culture tested, >=99.0%; Acetylsalicylic acid for peak identification, European Pharmacopoeia (EP) Reference Standard; InChI=1/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12; 11126-35-5; Aspirin (Acetyl Salicylic Acid), Pharmaceutical Secondary Standard; Certified Reference Material

    Click to Show/Hide
Structure
Formula
C9H8O4
IUPAC Name
2-acetyloxybenzoic acid
Canonical SMILES
CC(=O)OC1=CC=CC=C1C(=O)O
InChI
InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
InChIKey
BSYNRYMUTXBXSQ-UHFFFAOYSA-N
PubChem CID
2244
Full List of Ferroptosis Target Related to This Drug
Prostaglandin G/H synthase 2 (PTGS2)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Marker
Responsed Disease Chronic kidney disease ICD-11: GB61
 Disease Info 
Pathway Response Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model HK-2 cells Normal Homo sapiens CVCL_0302
In Vivo Model
These mice were on eight weeks old male DBA/2J background (n = 36, HFK Bioscience, Beijing, China). They were randomized one of the six groups: control normal mice group (NC); diabetic mice group (DM); diabetic mice group (Fer-1), who intraperitoneal injected Fer-1 (Selleck, Houston, TX, USA); diabetic mice group (vehicle-P), who intraperitoneal injected 1% dimethyl sulfoxide (DMSO); diabetic mice group (As), who intragastric administrated Aspirin (Solarbio, Beijing, China); diabetic mice group (vehicle-G), who intragastric administrated 0.5% sodium carboxymethyl cellulose (Na-CMC; Solarbio, Beijing, China). Diabetes models were induced with 5 consecutive days of a single intraperitoneal injection of streptozotocin 40 mg/kg (dissolved in 0.1 M citrate buffer, pH 4.5; SigmaAldrich, St Louis, MO, USA). Control mice only was injected the same volume of citrate buffer. In the Fer-1 or vehicle-P groups, the diabetic mice were treated respectively with Fer-1 (2.5 umol/kg, dissolved in 1% DMSO) or 1% DMSO during the duration of treatment for 12-week every day. And in the AS and vehicle-G groups, the diabetic mice were treated respectively with aspirin (50 mg/kg, dissolved in 0.5% Na-CMC) or 0.5% Na-CMC for 12-week every day.

    Click to Show/Hide
Response regulation Aspirin can upregulate SLC7A11 and GPX4 expression by suppressing COX2. Our results demonstrated that ferroptosis in renal tubular cells contributes to Diabetic kidney disease (DKD) development and that diabetes-related ferroptosis was inhibited through the downregulation of COX2 by aspirin, thus retarding the progression of DKD.
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Chronic kidney disease ICD-11: GB61
 Disease Info 
Pathway Response Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model HK-2 cells Normal Homo sapiens CVCL_0302
In Vivo Model
These mice were on eight weeks old male DBA/2J background (n = 36, HFK Bioscience, Beijing, China). They were randomized one of the six groups: control normal mice group (NC); diabetic mice group (DM); diabetic mice group (Fer-1), who intraperitoneal injected Fer-1 (Selleck, Houston, TX, USA); diabetic mice group (vehicle-P), who intraperitoneal injected 1% dimethyl sulfoxide (DMSO); diabetic mice group (As), who intragastric administrated Aspirin (Solarbio, Beijing, China); diabetic mice group (vehicle-G), who intragastric administrated 0.5% sodium carboxymethyl cellulose (Na-CMC; Solarbio, Beijing, China). Diabetes models were induced with 5 consecutive days of a single intraperitoneal injection of streptozotocin 40 mg/kg (dissolved in 0.1 M citrate buffer, pH 4.5; SigmaAldrich, St Louis, MO, USA). Control mice only was injected the same volume of citrate buffer. In the Fer-1 or vehicle-P groups, the diabetic mice were treated respectively with Fer-1 (2.5 umol/kg, dissolved in 1% DMSO) or 1% DMSO during the duration of treatment for 12-week every day. And in the AS and vehicle-G groups, the diabetic mice were treated respectively with aspirin (50 mg/kg, dissolved in 0.5% Na-CMC) or 0.5% Na-CMC for 12-week every day.

    Click to Show/Hide
Response regulation Aspirin can upregulate SLC7A11 and GPX4 expression by suppressing COX2. Our results demonstrated that ferroptosis in renal tubular cells contributes to Diabetic kidney disease (DKD) development and that diabetes-related ferroptosis was inhibited through the downregulation of COX2 by aspirin, thus retarding the progression of DKD.
Cystine/glutamate transporter (SLC7A11)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Chronic kidney disease ICD-11: GB61
 Disease Info 
Pathway Response Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model HK-2 cells Normal Homo sapiens CVCL_0302
In Vivo Model
These mice were on eight weeks old male DBA/2J background (n = 36, HFK Bioscience, Beijing, China). They were randomized one of the six groups: control normal mice group (NC); diabetic mice group (DM); diabetic mice group (Fer-1), who intraperitoneal injected Fer-1 (Selleck, Houston, TX, USA); diabetic mice group (vehicle-P), who intraperitoneal injected 1% dimethyl sulfoxide (DMSO); diabetic mice group (As), who intragastric administrated Aspirin (Solarbio, Beijing, China); diabetic mice group (vehicle-G), who intragastric administrated 0.5% sodium carboxymethyl cellulose (Na-CMC; Solarbio, Beijing, China). Diabetes models were induced with 5 consecutive days of a single intraperitoneal injection of streptozotocin 40 mg/kg (dissolved in 0.1 M citrate buffer, pH 4.5; SigmaAldrich, St Louis, MO, USA). Control mice only was injected the same volume of citrate buffer. In the Fer-1 or vehicle-P groups, the diabetic mice were treated respectively with Fer-1 (2.5 umol/kg, dissolved in 1% DMSO) or 1% DMSO during the duration of treatment for 12-week every day. And in the AS and vehicle-G groups, the diabetic mice were treated respectively with aspirin (50 mg/kg, dissolved in 0.5% Na-CMC) or 0.5% Na-CMC for 12-week every day.

    Click to Show/Hide
Response regulation Aspirin can upregulate SLC7A11 and GPX4 expression by suppressing COX2. Our results demonstrated that ferroptosis in renal tubular cells contributes to Diabetic kidney disease (DKD) development and that diabetes-related ferroptosis was inhibited through the downregulation of COX2 by aspirin, thus retarding the progression of DKD.
References
Ref 1 Aspirin mediates protection from diabetic kidney disease by inducing ferroptosis inhibition. PLoS One. 2022 Dec 14;17(12):e0279010. doi: 10.1371/journal.pone.0279010. eCollection 2022.